Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ENZY's Cash-to-Debt is ranked higher than
73% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ENZY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: 5008.86 Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
ENZY's Equity-to-Asset is ranked higher than
90% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ENZY: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.89 Max: 0.93
Current: 0.93
0.6
0.93
Piotroski F-Score: 6
Altman Z-Score: 12.72
Beneish M-Score: -2.95
WACC vs ROIC
8.22%
-3.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -6.53
ENZY's Operating Margin % is ranked higher than
68% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ENZY: -6.53 )
Ranked among companies with meaningful Operating Margin % only.
ENZY' s Operating Margin % Range Over the Past 10 Years
Min: -6.53  Med: 13.15 Max: 18.1
Current: -6.53
-6.53
18.1
Net Margin % -6.13
ENZY's Net Margin % is ranked higher than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ENZY: -6.13 )
Ranked among companies with meaningful Net Margin % only.
ENZY' s Net Margin % Range Over the Past 10 Years
Min: -6.13  Med: 12.95 Max: 17.54
Current: -6.13
-6.13
17.54
ROE % -2.11
ENZY's ROE % is ranked higher than
74% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. ENZY: -2.11 )
Ranked among companies with meaningful ROE % only.
ENZY' s ROE % Range Over the Past 10 Years
Min: -3.14  Med: 4.12 Max: 6.52
Current: -2.11
-3.14
6.52
ROA % -1.94
ENZY's ROA % is ranked higher than
76% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ENZY: -1.94 )
Ranked among companies with meaningful ROA % only.
ENZY' s ROA % Range Over the Past 10 Years
Min: -1.98  Med: 5.18 Max: 12.16
Current: -1.94
-1.98
12.16
ROC (Joel Greenblatt) % -4.12
ENZY's ROC (Joel Greenblatt) % is ranked higher than
76% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ENZY: -4.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.12  Med: 12.6 Max: 28.12
Current: -4.12
-4.12
28.12
3-Year Revenue Growth Rate -33.10
ENZY's 3-Year Revenue Growth Rate is ranked lower than
79% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ENZY: -33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -33.1 Max: -5
Current: -33.1
3-Year EBITDA Growth Rate -88.80
ENZY's 3-Year EBITDA Growth Rate is ranked lower than
100% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ENZY: -88.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ENZY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88.8 Max: -4.4
Current: -88.8
GuruFocus has detected 3 Warning Signs with Enzymotec Ltd $ENZY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZY's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENZY Guru Trades in Q1 2016

John Paulson 4,224,139 sh (-0.33%)
Julian Robertson 1,143,145 sh (-1.69%)
Jim Simons 181,000 sh (-16.86%)
» More
Q2 2016

ENZY Guru Trades in Q2 2016

Jim Simons 241,000 sh (+33.15%)
John Paulson 4,224,139 sh (unchged)
Julian Robertson 577,407 sh (-49.49%)
» More
Q3 2016

ENZY Guru Trades in Q3 2016

Julian Robertson 677,548 sh (+17.34%)
Jim Simons 258,300 sh (+7.18%)
John Paulson 4,205,980 sh (-0.43%)
» More
Q4 2016

ENZY Guru Trades in Q4 2016

Jim Simons 290,000 sh (+12.27%)
John Paulson 4,205,980 sh (unchged)
Julian Robertson 677,548 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:OTCPK:ELVAF, NAS:MNOV, NAS:TRVN, NAS:CASC, OTCPK:OXBDF, NAS:NVLN, NAS:CYAD, NAS:FATE, NAS:SRNE, NAS:VTVT, NAS:PPHM, OTCPK:SPRWF, NAS:STML, NAS:ABEO, NAS:CDXS, OTCPK:SPHRY, NAS:CEMP, NAS:PETX, AMEX:MTNB, NAS:SELB » details
Traded in other countries:EZ4.Germany,
Enzymotec Ltd develops, manufactures, markets & sells innovative bio-functional lipid ingredients, and final products, based on sophisticated proprietary processes & technologies. The Company's segments include Nutrition Segment & VAYA Pharma Segment.

Top Ranked Articles about Enzymotec Ltd

Julian Robertson Sells Half of Stake in John Paulson-Backed Company Hedge fund pioneer was fourth largest shareholder of 'medical foods' company
Roughly a year after starting to invest in the company, Julian Robertson (Trades, Portfolio) has chopped half his stake in Enzymotec Ltd. (NASDAQ:ENZY), a maker of nutritional ingredients and medical foods. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.49
ENZY's PB Ratio is ranked higher than
84% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ENZY: 1.49 )
Ranked among companies with meaningful PB Ratio only.
ENZY' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.48 Max: 11.01
Current: 1.49
0.91
11.01
PS Ratio 4.23
ENZY's PS Ratio is ranked higher than
76% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ENZY: 4.23 )
Ranked among companies with meaningful PS Ratio only.
ENZY' s PS Ratio Range Over the Past 10 Years
Min: 1.26  Med: 3.55 Max: 5.88
Current: 4.23
1.26
5.88
Price-to-Operating-Cash-Flow 139.68
ENZY's Price-to-Operating-Cash-Flow is ranked lower than
91% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. ENZY: 139.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.93  Med: 24.11 Max: 686.67
Current: 139.68
10.93
686.67
EV-to-EBITDA 4480.92
ENZY's EV-to-EBITDA is ranked lower than
100% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. ENZY: 4480.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 18.8 Max: 4696.4
Current: 4480.92
6.3
4696.4
Current Ratio 9.06
ENZY's Current Ratio is ranked higher than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ENZY: 9.06 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 1.78  Med: 7.02 Max: 9.06
Current: 9.06
1.78
9.06
Quick Ratio 6.11
ENZY's Quick Ratio is ranked higher than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ENZY: 6.11 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 5.59 Max: 6.11
Current: 6.11
1.27
6.11
Days Inventory 519.37
ENZY's Days Inventory is ranked lower than
95% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. ENZY: 519.37 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 251.79 Max: 519.37
Current: 519.37
121.07
519.37
Days Sales Outstanding 76.82
ENZY's Days Sales Outstanding is ranked lower than
60% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. ENZY: 76.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.82  Med: 108.17 Max: 120.92
Current: 76.82
76.82
120.92
Days Payable 105.65
ENZY's Days Payable is ranked higher than
67% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ENZY: 105.65 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 102.78  Med: 106.61 Max: 145.45
Current: 105.65
102.78
145.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
ENZY's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ENZY: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.8  Med: -2 Max: 0
Current: -2
-14.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.89
ENZY's Price-to-Net-Cash is ranked lower than
70% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. ENZY: 11.89 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.72  Med: 9.62 Max: 14.2
Current: 11.89
7.72
14.2
Price-to-Net-Current-Asset-Value 2.85
ENZY's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ENZY: 2.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.12  Med: 2.97 Max: 6.51
Current: 2.85
2.12
6.51
Price-to-Tangible-Book 1.48
ENZY's Price-to-Tangible-Book is ranked higher than
88% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ENZY: 1.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 1.5 Max: 4.94
Current: 1.48
1.1
4.94
Price-to-Median-PS-Value 1.20
ENZY's Price-to-Median-PS-Value is ranked lower than
61% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ENZY: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 0.98 Max: 1.27
Current: 1.2
0.58
1.27
Earnings Yield (Greenblatt) % -1.54
ENZY's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ENZY: -1.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.6  Med: 4.15 Max: 13.9
Current: -1.54
-1.6
13.9

More Statistics

Revenue (TTM) (Mil) $47.70
EPS (TTM) $ -0.13
Beta0.86
Short Percentage of Float0.84%
52-Week Range $5.20 - 9.32
Shares Outstanding (Mil)22.94

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.50
EPS without NRI ($) 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Julian Robertson Adds to Multiple Positions in 3rd quarter Dec 20 2016 
Julian Robertson Cuts Half of Stake in Paulson-Backed Company Jul 01 2016 
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
ENZYMOTEC LTD. Financials Mar 22 2017
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016 Mar 16 2017
Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders Mar 10 2017
Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO Mar 09 2017
Enzymotec reports 4Q loss Feb 22 2017
Enzymotec reports 4Q loss Feb 22 2017
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results Feb 22 2017
Enzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results Feb 06 2017
2016-12-21 Enzymatica AB: Top-line results of new clinical trial Dec 21 2016
2016-12-19 Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ) Dec 19 2016
Does Enzymotec Ltd (ENZY) Stack Up To Its Peers In This Metric? Dec 15 2016
What Makes Enzymotec (ENZY) a Strong Sell? Dec 12 2016
2016-12-01 Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors Dec 01 2016
2016-12-01 Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (publ) Dec 01 2016
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Edited Transcript of ENZY earnings conference call or presentation 16-Nov-16 1:30pm GMT Nov 16 2016
Enzymotec Ltd. Announces Departure of its CEO Nov 16 2016
2016-11-03 Enzymatica AB: ColdZyme® sales continue to perform well Nov 03 2016
2016-11-02 Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health Nov 02 2016
Enzymotec to Report Third Quarter 2016 Financial Results Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)